美东时间6月24日周二盘前，远程医疗公司Hims & Hers Health Inc.（股票代码：HIMS）股价大涨5.10%，显示投资者可能正在重新评估该公司与诺和诺德（Novo Nordisk）终止合作关系的影响。
此前一天，丹麦制药巨头诺和诺德宣布终止与Hims & Hers的减肥药物销售合作，理由是对方涉嫌违反联邦法律，进行大规模配制药物销售并存在误导性营销行为。这一消息导致Hims & Hers股价在周一交易中大幅下跌，跌幅一度超过34%。
今日盘前的反弹表明，部分投资者可能认为市场对合作终止消息的反应过度，开始重新评估Hims & Hers的长期发展前景。然而，该公司未来在减肥药物市场的策略调整及其对业务的潜在影响仍有待观察。分析师指出，虽然短期内公司可能面临挑战，但其在远程医疗领域的优势地位仍然存在，投资者需要密切关注公司的后续发展动向。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.